Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.

A sales partner offered a ray of hope that this company couldn't for itself.

Seek Labs, a private TechBio company building a programmable disease response platform to detect, protect, and counter disease threats, has been awarded $2 million from the U.S. D ...

Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage ...

Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru crafted a bespoke treatment that has successfully corrected the genetic ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...

Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after ...

Researchers developed a CRISPR-based system that spreads through bacterial populations to disable antibiotic resistance genes ...